Features

The upcoming Aerosols–Inhalation and Nasal Drug Products Workshop sponsored by the United States Pharmacopoeia’s General Chapters-Dosage Forms Expert Committee will take place at USP headquarters in Rockville, MD on December 12 and 13, and the… Read more . . .

The 2011 Drug Delivery to the Lungs (DDL) Conference, which takes place December 7-9 in Edinburgh, UK, will highlight a particularly strong field of scientific presentations from both established industry experts and up-and-coming young researchers,… Read more . . .

OINDP researchers with a particular interest in powder flow and rheology should take note that poster abstract submission and early registration for Powder Flow 2011 end on November 4. The meeting is organized by the… Read more . . .

The 2011 annual meeting of the American Association of Pharmaceutical Scientists in Washington, DC, which took place from October 23-27, included presentations of research related to OINDPs in several formats: a pre-workshop on “Developing Pharmaceutical… Read more . . .

Over the past few months, the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ) has issued several statistical briefs and a research finding regarding rising expenditures for asthma medications used… Read more . . .

Armstrong Pharmaceuticals, the manufacturer of the over-the-counter epinephrine MDI Primatene Mist, has been warning consumers to stock up on the product prior to its phaseout at the end of 2011, . . . .Read more Read more . . .

On or about September 6, 2011, United States District Court Judge William G. Young will hold a hearing to issue sanctions against InnovaSystems for contempt of court, having ruled that Innova has violated a permanent… Read more . . .

Mark Copley of Copley Scientific answers questions about upcoming changes to nebulizer testing requirements. Q: What are the new nebulizer testing requirements, and when do they come into force? A: Both the United States Pharmacopoeia… Read more . . .

Acknowledging that in its treatment of asthma and COPD, “we deliver health outcomes that fall some way behind those achieved by the best-performing countries, or the outcomes public health specialists and clinicians tell us are… Read more . . .